Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small cell lung cancer: A real-world, multicenter, retrospective, controlled study in China

Abstract

This RW study in China demonstrated improved clinical outcomes of atezolizumab along with EP for ES-SCLC, particularly in the chemosensitive population. These results align with the results of the IMpower133 study, although the impact of this treatment modality on OS warrants additional follow-up studies.